Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies

Robles-Planells, Claudia; Sánchez-Guerrero, Giselle; Barrera-Avalos, Carlos; Matiacevich, Silvia; Rojo, Leonel E.; Pavez, Jorge; Salas-Huenuleo, Edison; Kogan, Marcelo J.; Escobar, Alejandro; Milla, Luis A.; Fernández, Ricardo; Imarai, Mónica; Spencer, Eugenio; Huidobro‐Toro, J. Pablo; Acuña-Castillo, Claudio

doi:10.1155/2020/8680692

Cited by 15 publications

(5 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The size of chitosan-based NPs prepared by various methods presented in Table 1 is very wide-ranging, from 32.7 [ 35 ] to 1100 ± 20 nm [ 34 ] depending on the preparation methods and on the targeted application. Some methods produce NPs with a very broad size range, which leads to difficulties in size control.…”

Section: Physico-chemical Aspects Of the Protein Corona Formationmentioning

confidence: 99%

See 1 more Smart Citation

Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications

et al. 2020

View full text Add to dashboard Cite

Chitosan is a polymer that is extensively used to prepare nanoparticles (NPs) with tailored properties for applications in many fields of human activities. Among them, targeted drug delivery, especially when cancer therapy is the main interest, is a major application of chitosan-based NPs. Due to its positive charges, chitosan is used to produce the core of the NPs or to cover NPs made from other types of polymers, both strategies aiming to protect the carried drug until NPs reach the target sites and to facilitate the uptake and drug delivery into these cells. A major challenge in the design of these chitosan-based NPs is the formation of a protein corona (PC) upon contact with biological fluids. The composition of the PC can, to some extent, be modulated depending on the size, shape, electrical charge and hydrophobic / hydrophilic characteristics of the NPs. According to the composition of the biological fluids that have to be crossed during the journey of the drug-loaded NPs towards the target cells, the surface of these particles can be changed by covering their core with various types of polymers or with functionalized polymers carrying some special molecules, that will preferentially adsorb some proteins in their PC. The PC’s composition may change by continuous processes of adsorption and desorption, depending on the affinity of these proteins for the chemical structure of the surface of NPs. Beside these, in designing the targeted drug delivery NPs one can take into account their toxicity, initiation of an immune response, participation (enhancement or inhibition) in certain metabolic pathways or chemical processes like reactive oxygen species, type of endocytosis of target cells, and many others. There are cases in which these processes seem to require antagonistic properties of nanoparticles. Products that show good behavior in cell cultures may lead to poor in vivo results, when the composition of the formed PC is totally different. This paper reviews the physico-chemical properties, cellular uptake and drug delivery applications of chitosan-based nanoparticles, specifying the factors that contribute to the success of the targeted drug delivery. Furthermore, we highlight the role of the protein corona formed around the NP in its intercellular fate.

show abstract

Section: Physico-chemical Aspects Of the Protein Corona Formationmentioning

confidence: 99%

“…The in vivo transfection slightly delayed tumor growth. Expression of ISAV fusion protein using chitosan NPs induced fusion of melanoma cells and slight in vivo antitumoral effect in comparison to chitosan treatment [ 35 ].…”

Section: Applications In Drug Delivery Of Chitosan-based Nps-pc Comentioning

confidence: 99%

Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Chitosan/pIRES-ARV complexes were synthesized at an N/P ratio of 20 as described in Materials and Methods and as described previously [18]. Under these conditions, the formation of the complexes between pIRES-ARV and CH was confirmed by electrophoretic migration delay in comparison to pIRES-ARV alone, indicating a successful complexation interaction with chitosan (Figure 1(a)).…”

Section: Nanoparticle Characterizationmentioning

confidence: 88%

Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma

Robles-Planells

Barrera-Avalos

Rojo

et al. 2020

BioMed Research International

Self Cite

View full text Add to dashboard Cite

Reovirus is known to have an anticancer effect in both the preclinical and clinical assays. Current evidence suggests that the reovirus-mediated impact on tumor growth depends on the activation of specific antitumor immune responses. A feasible explanation for the oncolytic effects and immune system activation is through the expression of the fusogenic reovirus protein. In this work, we evaluated the in vivo antitumor effects of the expression of fusogenic protein p10 of avian reovirus (ARV-p10). We used chitosan nanoparticles (CH-NPs) as a vehicle for the ARV-p10 DNA in murine B16 melanoma models both in vitro and in vivo. We confirmed that ARV-p10 delivery through a chitosan-based formulation (ARV-p10 CH-NPs) was capable of inducing cell fusion in cultured melanoma cells, showing a mild cytotoxic effect. Interestingly, intratumor injection of ARV-p10 CH-NPs delayed tumor growth, without changing lymphoid populations in the tumor tissue and spleen. The injection of chitosan nanoparticles (CH-NPs) also delayed tumor growth, suggesting the nanoparticle itself would attack tumor cells. In conclusion, we proved that in vitro ARV-p10 protein expression using CH-NPs in murine melanoma cells induces a cytotoxic effect associated with its cell fusion. Further studies are necessary for establishing a protocol for efficient in vivo DNA delivery of fusion proteins to produce an antitumoral effect.

show abstract

“…Similarly, virus-derived proteins can be exploited as oncolytic anticancer agents. In a previous study, fusogenic protein of infectious salmon anemia virus (ISAV-F) was delivered to B16 tumor cells using chitosan nanoparticles [ 140 ]. The expression of fusogenically active ISAV-F protein decreased cell viability in vitro and delayed tumor growth in vivo without altering the lymphoid population in the tumor and spleen, demonstrating the direct oncolytic property of ISAV-F protein.…”

Section: Immunotherapy Approaches Using Nanocarriersmentioning

confidence: 99%

Nanocarriers for cancer nano-immunotherapy

Rana

Baig

et al. 2022

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

The host immune system possesses an intrinsic ability to target and kill cancer cells in a specific and adaptable manner that can be further enhanced by cancer immunotherapy, which aims to train the immune system to boost the antitumor immune response. Several different categories of cancer immunotherapy have emerged as new standard cancer therapies in the clinic, including cancer vaccines, immune checkpoint inhibitors, adoptive T cell therapy, and oncolytic virus therapy. Despite the remarkable survival benefit for a subset of patients, the low response rate and immunotoxicity remain the major challenges for current cancer immunotherapy. Over the last few decades, nanomedicine has been intensively investigated with great enthusiasm, leading to marked advancements in nanoparticle platforms and nanoengineering technology. Advances in nanomedicine and immunotherapy have also led to the emergence of a nascent research field of nano-immunotherapy, which aims to realize the full therapeutic potential of immunotherapy with the aid of nanomedicine. In particular, nanocarriers present an exciting opportunity in immuno-oncology to boost the activity, increase specificity, decrease toxicity, and sustain the antitumor efficacy of immunological agents by potentiating immunostimulatory activity and favorably modulating pharmacological properties. This review discusses the potential of nanocarriers for cancer immunotherapy and introduces preclinical studies designed to improve clinical cancer immunotherapy modalities using nanocarrier-based engineering approaches. It also discusses the potential of nanocarriers to address the challenges currently faced by immuno-oncology as well as the challenges for their translation to clinical applications. Graphical abstract

show abstract

Chitosan-Based Nanoparticles for Intracellular Delivery of ISAV Fusion Protein cDNA into Melanoma Cells: A Path to Develop Oncolytic Anticancer Therapies

Cited by 15 publications

References 31 publications

Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications

Understanding the Factors Influencing Chitosan-Based Nanoparticles-Protein Corona Interaction and Drug Delivery Applications

Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma

Nanocarriers for cancer nano-immunotherapy

Contact Info

Product

Resources

About